{"entity":{"id":"nct06008119","kind":"trial","name":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 3 trial of Tunlametinib run by Shanghai Kechow Pharma, Inc. in colorectal cancer, now recruiting.","summary":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06008119 by Shanghai Kechow Pharma, Inc., with 165 participants planned, started 2023-10-25. Conditions listed: Colorectal Cancer Metastatic. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06008119","url":"https://clinicaltrials.gov/study/NCT06008119"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal","braf-v600e-colorectal"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["tunlametinib"],"companies":["shanghai-kechow-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06008119","phase":"3","setting":"A Multicenter, Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","sponsor":"Shanghai Kechow Pharma, Inc.","participation":[{"nct":"NCT06008119","source":"https://clinicaltrials.gov/study/NCT06008119","fetchedAt":"2026-10-07T16:54:05.353Z","studySha256":"0ee1546c76bac93b9bd376e66fd673fe83f64e00ae37c1b743b2bedcae606f3b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-09","leadSponsor":"Shanghai Kechow Pharma, Inc.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":165,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-10-25","startedType":"actual","enrolled":165,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06008119/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/"}],"company":[{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","route":"/companies/shanghai-kechow-pharma/"}]}}